Cabaletta Bio (NASDAQ:CABA – Get Free Report) and Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Valuation and Earnings
This table compares Cabaletta Bio and Outlook Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cabaletta Bio | N/A | N/A | -$67.68 million | ($2.15) | -0.78 |
| Outlook Therapeutics | N/A | N/A | -$75.37 million | ($7.42) | -0.20 |
Cabaletta Bio is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Cabaletta Bio | N/A | -50.10% | -45.49% |
| Outlook Therapeutics | N/A | N/A | -225.12% |
Institutional & Insider Ownership
11.2% of Outlook Therapeutics shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by company insiders. Comparatively, 4.8% of Outlook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Cabaletta Bio and Outlook Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cabaletta Bio | 0 | 1 | 6 | 1 | 3.00 |
| Outlook Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
Cabaletta Bio currently has a consensus price target of $22.71, indicating a potential upside of 1,260.14%. Outlook Therapeutics has a consensus price target of $10.20, indicating a potential upside of 584.56%. Given Cabaletta Bio’s stronger consensus rating and higher possible upside, equities analysts clearly believe Cabaletta Bio is more favorable than Outlook Therapeutics.
Volatility and Risk
Cabaletta Bio has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Summary
Cabaletta Bio beats Outlook Therapeutics on 9 of the 12 factors compared between the two stocks.
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
About Outlook Therapeutics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.
